Guided Therapeutics (GTHP) Convertible Debt (2016 - 2025)
Historic Convertible Debt for Guided Therapeutics (GTHP) over the last 12 years, with Q1 2025 value amounting to $35000.0.
- Guided Therapeutics' Convertible Debt fell 9690.27% to $35000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $35000.0, marking a year-over-year decrease of 9690.27%. This contributed to the annual value of $14000.0 for FY2024, which is N/A changed from last year.
- Per Guided Therapeutics' latest filing, its Convertible Debt stood at $35000.0 for Q1 2025, which was down 9690.27% from $14000.0 recorded in Q4 2024.
- Guided Therapeutics' Convertible Debt's 5-year high stood at $1.1 million during Q1 2024, with a 5-year trough of $14000.0 in Q4 2024.
- Moreover, its 5-year median value for Convertible Debt was $999500.0 (2022), whereas its average is $845000.0.
- As far as peak fluctuations go, Guided Therapeutics' Convertible Debt soared by 97843.14% in 2021, and later crashed by 9690.27% in 2025.
- Quarter analysis of 5 years shows Guided Therapeutics' Convertible Debt stood at $820000.0 in 2021, then grew by 27.56% to $1.0 million in 2022, then fell by 6.12% to $982000.0 in 2023, then tumbled by 98.57% to $14000.0 in 2024, then skyrocketed by 150.0% to $35000.0 in 2025.
- Its last three reported values are $35000.0 in Q1 2025, $14000.0 for Q4 2024, and $1.1 million during Q3 2024.